Professor Suzanne Garland is an internationally recognized clinical microbiologist and sexual health physician, with particular expertise in infectious diseases as they pertain to reproductive health and the neonate. With her team, Prof Garland, has been a leader in the role of patient self-collected genital sampling in the detection by molecular techniques (polymerase chain reaction (PCR) of reproductive tract infections, particularly those sexually transmitted, such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and especially human papillomaviruses (HPV) [well before there were diagnostic commercial assays] and has published extensively on clinical epidemiology of sexually transmitted infections in Australia.
She has been involved in defining HPV in cervical dysplasia, cervical cancer, plus the healthy population within Australia, as well as being chief investigator defining the prevalence of HPV genotypes in urban, rural, indigenous and non-indigenous Australian women (WHINURS project), pre HPV vaccination program in Australia. She has been chief investigator of two 4-year follow-up clinical trials of prophylactic HPV vaccines in young women, plus one in mid-age women. She currently leads an HPV vaccine effectiveness trial (VACCINE) in Australia which will be informative globally, particularly with the WHINURS data as baseline with which to compare outcomes post vaccination.
Prof Garland has a keen interest in probiotics in neonates and led the world’s largest RCT, the results of which have changed neonatal practice globally. She has also embraced new technologies utilizing e-health as novel recruitment methods, as well is interventions in a young female health initiative (YFHI).
She is a regular Advisor to the WHO, largely in the area of sexually transmitted infection diagnosis, for prophylactic HPV vaccines, as well as international standards for HPV DNA assays. She has published extensively in more than 550 peer-reviewed journals, 35 chapters of books, as well as being invited to deliver keynote and plenary presentations at national and international meetings. She is the Inaugural and Past President of the newly formed society, AOGIN (Asian Oceania Research Organization on Genital Infection and Neoplasia), which brings together clinicians and scientists within the Asian and Oceania regions and whose work is related to genital infections and neoplasia. AOGIN aims to promote and develop, at an Asia-Oceania level, research, training, screening, prevention and information concerning genital infections, pre-cancers and cancers in women and brings together representatives from the Asia-Oceania region, of a multidisciplinary specialist areas including: gynaecologists, sexual health physicians, dermatologists, pathologists, molecular biologists, oncologists and basic scientists.
In recognition of her clinically based research, “Infectious Diseases Research in Reproductive Health; Particularly of Women and Babies" Prof Garland was selected to in 2010 by NHMRC for “one of the 10 Best Research Projects “.